Alsagaby Suliman A
Department of Medical Laboratories Sciences, College of Applied Medical Sciences, Majmaah University, Majmaah 11932, PO Box 1712, Saudi Arabia.
Stem Cells Int. 2021 Feb 17;2021:6633386. doi: 10.1155/2021/6633386. eCollection 2021.
Hematologic cancer encompasses the heterogeneous group of neoplasms that affect different stages of blood cell linages. Despite the significant improvements made in the new modalities of anticancer therapy, many forms of blood cancer remain untreatable, putting the afflicted patients at high risk of death. Therefore, there has been an urgent need for novel therapy to improve the clinical outcomes of patients with blood cancer. Mesenchymal stem cell-derived extracellular vesicles (MSC-EVs) have been reported to possess an anticancer activity. This review discusses (i) the therapeutic potential of MSC-EVs against blood cancer, (ii) the possibility of using EVs from sources other than MSCs as a mean for blood cancer vaccination and drug delivery, and (iii) areas to be optimized for MSC-EV-based clinical application on blood malignancies.
血液系统癌症包括影响血细胞谱系不同阶段的一组异质性肿瘤。尽管抗癌治疗的新方法取得了显著进展，但许多形式的血癌仍然无法治愈，使患病患者面临高死亡风险。因此，迫切需要新的治疗方法来改善血癌患者的临床结局。据报道，间充质干细胞衍生的细胞外囊泡（MSC-EVs）具有抗癌活性。本综述讨论了（i）MSC-EVs对血癌的治疗潜力，（ii）使用来自MSC以外来源的细胞外囊泡作为血癌疫苗接种和药物递送手段的可能性，以及（iii）基于MSC-EV的血液恶性肿瘤临床应用需要优化的领域。
